Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

UPDATE: ‘Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28’

By Bill Haddad
September 16, 7:16 AM
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 /PRNewswire/ -- Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim

NTLA

Read More
1 minute read

Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report

By Vandana Singh
September 13, 2:36 PM
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years. 

ABBV

Read More
2 minute read

Regeneron Pharmaceuticals Announced 63% Combined Pathologic Response Rate for Neoadjuvant Libtayo Monotherapy in Stage II to IV Resectable CSCC Per Primary Analysis of a Confirmatory Phase 2 Trial; Data Presented at ESMO

By Charles Gross
September 12, 4:58 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC).

REGN

Read More
1 minute read

‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added

By Vandana Singh
September 9, 11:14 AM
Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625.  The analyst…

REGN